Применение молекулярно-генетического анализа для выбора противоопухолевой цитостатической терапии

молекулярные маркеры, химиочувствительность, химиорезистентность, генотипирование, индивидуализация противоопухолевой терапии

1. Chabner B.A., Roberts T.G. Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5(1):65—72.

2. Robert J., Vekris A., Pourquier P., Bonnet J. Predicting drug response based on gene expression. Crit Rev Oncol Hematol 2004;51(3):205—27.

3. Robert J., Morvan V.L., Smith D. et al. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005;54(3):171—96.

4. Aschele C., Lonardi S., Monfardini S. Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002;28(1):27—47.

5. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003;8(3):132—8.

6. Watters J.W., McLeod H.L. Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 2003;1603(2):99—111.

7. Ciccolini J., Evrard A., Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents 2004;4(2):71—81.

8. Formentini A., Henne-Bruns D., Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg 2004;389(5):405—13.

9. van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40(7):939—50.

10. Kawakami K., Graziano F., Watanabe G. et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 2005;11(10):3778—83.

11. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 2005;23(6):533—7.

12. Stohlmacher J. Pharmacogenetics in gastrointestinal tumors. Onkologie 2005;28(8—9):435—40.

13. Ochiai T., Nishimura K., Noguchi H. et al. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 2006;118(12):3084—8.

14. Rosell R., Cobo M., Isla D. et al. Applications of genomics in NSCLC. Lung Cancer 2005;50 (Suppl 2):S33—40.

15. Liu L., Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006;12(2):328—31.

16. Coon J.S., Marcus E., Gupta-Burt S. et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8(4):1061—7.

17. Di Leo A., Gancberg D., Larsimont D. et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8(5):1107—16.

18. MacGrogan G., Rudolph P., Mascarel Id I. et al. DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer 2003;89(4):666—71.

19. Park K., Kim J., Lim S., Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003;39(5):631—4.

20. Knoop A.S., Knudsen H., Balslev E. et al; Danish Breast Cancer Cooperative Group. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23(30):7483—90.

21. Scandinavian Breast Group Trial 9401; Tanner M., Isola J., Wiklund T. et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006;24(16):2428—36.

22. Rouzier R., Rajan R., Wagner P. et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005;102(23):8315—20.

23. Seve P., Isaac S., Tredan O. et al. Expression of class III beta-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11(15):5481—6.

24. Seve P., Mackey J., Isaac S. et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4(12):2001—7.

25. Kim S.J., Miyoshi Y., Taguchi T. et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 2005;11(23):8425—30.

26. Urano N., Fujiwara Y., Doki Y. et al. Clinical significance of class III betatubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006;28(2):375—81.

27. Libra M., Navolanic P.M., Talamini R. et al. Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 2004;4:11.

28. Gonen M., Hummer A., Zervoudakis A. et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21(3):406—12.

29. Ichikawa W., Takahashi T., Suto K. et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 2004;91(7):1245—50.

30. Kidd E.A., Yu J., Li X. et al. Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005;11(7):2612—9.

31. Adlard J.W., Richman S.D., Seymour M.T., Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002;3(2):75—82.

32. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3(5):330—8.

33. Vincenzi B., Cesa A.L., Santini D. et al. Predictive factors for response to chemotherapy in colorectal cancer patients. Crit Rev Oncol Hematol 2004;52(1):45—60.

34. Toi M., Atiqur Rahman M., Bando H., Chow L.W. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005;6(3):158—66.

35. Ichikawa W., Uetake H., Shirota Y. et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidinebased chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89(8):1486—92.

36. Salonga D., Danenberg K.D., Johnson M. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6(4):1322—7.

37. Smorenburg C.H., Peters G.J., van Groeningen C.J. et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006;17(1):35—42.

38. Dabholkar M., Vionnet J., BostickBruton F. et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinumbased chemotherapy. J Clin Invest 1994;94(2):703—8.

39. Metzger R., Leichman C.G., Danenberg K.D. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16(1):309—16.

40. Shirota Y., Stoehlmacher J., Brabender J. et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19(23):4298—304.

41. Warnecke-Eberz U., Metzger R., Miyazono F. et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10(11):3794—9.

42. Joshi M.B., Shirota Y., Danenberg K.D. et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11(6):2215—21.

43. Lord R.V., Brabender J., Gandara D. et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8(7):2286—91.

44. Ma S., Egyhazi S., Ueno T. et al. O6- methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003;89(8):1517—23.

45. Ohno T., Hiraga J., Ohashi H. et al. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large Bcell lymphoma. Int J Hematol 2006;83(4):341—7.

46. Pollack I.F., Hamilton R.L., Sobol R.W. et al. O6-methylguanineDNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 2006;24(21):3431—7.

47. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin Chem 2005;51(3):494—503.

48. Molina R., Barak V., van Dalen A. et al. Tumor markers in breast cancerEuropean Group on Tumor Markers recommendations. Tumour Biol 2005;26(6):281—93.

49. Piccart-Gebhart M.J. Anthracyclines and the tailoring of treatment for early breast cancer. N Engl J Med 2006;354(20):2177—9.

50. Di Leo A., Cardoso F., Durbecq V. et al. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int J Clin Oncol 2002;7(4):245—53.

51. Braybrooke J.P., Levitt N.C., Joel S. et al. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression. Clin Cancer Res 2003;9(13): 4682—8.

52. Kamath K., Wilson L., Cabral F., Jordan MA. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005;280(13):12902—7.

53. Mozzetti S., Ferlini C., Concolino P. et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11(1):298—305.

54. Ferrandina G., Zannoni G.F., Martinelli E. et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12(9):2774—9.

55. Hasegawa S., Miyoshi Y., Egawa C. et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003;9(8):2992—7.

56. Iwao-Koizumi K., Matoba R., Ueno N. et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23(3):422—31.

57. Dervieux T., Meshkin B., Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005;573(1—2):180—94.

58. Innocenti F., Ratain M.J. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 2002;38(5):639—44.

59. McLeod H.L., Yu J. Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest 2003;21(4):630—40.

60. Tai H.L., Fessing M.Y., Bonten E.J. et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999;9(5):641—50.

61. Innocenti F., Ratain M.J. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther 2004;75(6):495—500.

62. Innocenti F., Vokes E.E., Ratain M.J. Irinogenetics: what is the right star? J Clin Oncol 2006;24(15):2221—4.

63. Toffoli G., Veronesi A., Boiocchi M., Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000;11(3):373—4.

64. Ulrich C.M., Yasui Y., Storb R. et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98(1):231—4.

65. Chiusolo P., Reddiconto G., Casorelli I. et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002;13(12):1915—8.

66. Toffoli G., Russo A., Innocenti F. et al. Effect of methylenetetrahydrofolate reductase 677C—>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003;103(3):294—9.